November 18, 2016

To,
The Manager,
Listing Department
National Stock Exchange of India Ltd
'Exchange Plaza'
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,

Sub: Updates - Alembic Pharmaceuticals Limited receives ANDA Approval for Telmisartan and Amlodipine Tablets

This is to inform the exchange that the Company has received approval for its abbreviated new drug application (ANDA) for Telmisartan and Amlodipine Tablets for various dosages from the Department of Health & Human Services, U.S. Food & Drug Administration (FDA). Please find enclosed herewith our press release.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

R. K. Baheti
Director – Finance & CFO

Encl: A/a.

PRESS RELEASE

18th November, 2016, Vadodara, India

Alembic Pharmaceuticals receives USFDA Approval for Telmisartan and Amlodipine Tablets

Alembic Pharmaceuticals Limited today announced that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Telmisartan and Amlodipine Tablets, 40 mg/5 mg, 40 mg/10 mg, 80 mg/5 mg, and 80 mg/10 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Twynsta® Tablets, 40 mg/5 mg, 40 mg/10 mg, 80 mg/5 mg, and 80 mg/10 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. Telmisartan and Amlodipine Tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to reduce blood pressure.

Alembic now has a total of 50 ANDA approvals (44 final approvals and 6 tentative approvals) from USFDA.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE:APLLTD) (BSE:533573)

For more information contact:

Ajay Kumar Desai Phone: +91 22 - 306 11681 Email: ajay.desai@alembic.co.in	Mitanshu Shah Phone: +91 265 - 3007630 Email: mitanshu.shah@alembic.co.in

ALEMBIC PHARMACEUTICALS LIMITED VADODARA 390 003.